natgillin/translations-raw huggingface dataset:
In another embodiment the invention is a compound for use according to statement 8, characterized in that said tumor diseases are solid tumors, preferably epithelial tumors, such as prostate carcinoma; mammary carcinoma; pancreatic carcinoma; lung carcinoma; gastrointestinal tract carcinoma, such as colon carcinoma; kidney cancer; thyroid carcinoma; uterine carcinoma; adrenal carcinoma. 
Spoj, naznačen time što je namijenjen upotrebi u skladu s patentnim zahtjevom 7 ili 8, naznačen time što su navedene tumorske bolesti čvrsti tumori, po mogućnosti tumori epitela, poželjnije gdje su tumori epitela karcinom prostate; karcinom dojke; karcinom gušterače; karcinom pluća; karcinom gastrointestinalnog sustava, poput karcinoma debelog crijeva; rak bubrega; karcinom štitnjače; karcinom maternice; ili karcinom nadbubrežne žlijezde.
A method according to claim 1, wherein the primary air flow has an initial speed of from 20 m/s to 150 m/s, preferably from 30 m/s to 120 m/s, more preferably from 40 m/s to 80 m/s, most preferably from 50 m/s to 70 m/s. 
Postupak sukladno bilo kojem prethodnom patentnom zahtjevu, pri čemu primarni protok zraka ima početnu brzinu od 20 m/s do 150 m/s, preporučljivo od 30 m/s do 120 m/s, još preporučljivije od 40 m/s do 80 m/s, najpreporučljivije od 50 m/s do 70 m/s.
at least 35% by weight of the dry matter of a legume protein fraction, 
najmanje 35 masenih % proteina mahunarki,
Also, the signals transmitted on these transmission channels Ch# 1 . . . 
prijenosa navedenih moduliranih pseudo-tokova podataka preko odgovarajućih prijenosnih kanala (Ch#1...
and Z2 are each absent or alkyl; and, Z3 is absent, -NH-, -SO2- or alkyl (wherein alkyl is optionally substituted at one or more positions by halogen, hydroxy, lower alkyl, lower alkoxy, carboxy or carbonylalkoxy) and wherein the term lower aldyl means an aldyl radical of up to 4 carbon atoms. 
i Z2 su svaki odsutan ili alkil; te je odsutan, -NH-, -SO2- ili alkil (pri čemu alkil je proizvoljno supstituiran u jednom ili više položaja sa halogenom, hidroksi, nižim alkilom, nižim alkoksi, karboksi ili karbonilalkoksi) i pri čemu izraz niži alkil znači radikal alkila sa do 4 atoma ugljika.
In some embodiments, a mutant GPCR is selected which has increased stability to any one or more of heat, a detergent, a chaotropic agent and an extreme of pH. 
Metoda iz Zahtjeva 1-7 naznačena time da se odabire mutacija GPCR-a koja ima povećanu stabilnost prema zagrijavanju, deterdžentu, kaotropu i ekstremnom pH.
Method according to claim 1, characterised in that step d) further comprises to compare the tagged relevant mobile phones with MSISDN numbers that are stored in a priority database, and remove the tag from mobile phones that have its MSISDN stored in the priority database, such that these are not prevented from normal communication, in and out from the specific geographical area, while alert messages are being sent. 
Postupak prema zahtjevu 1, naznačen time da korak d) dodatno sadrži usporedbu označenih odgovarajućih mobilnih telefona s MSISDN brojevima pohranjenim u prioritetnoj bazi podataka, te uklanjanje oznake s mobilnih telefona koji imaju njihov MSISDN pohranjen u prioritetnoj bazi podataka, tako da oni nisu spriječeni u normalnoj komunikaciji, u i izvan određenog zemljopisnog područja, tijekom slanja poruka upozorenja.
The process according to any of claims 1 to 10, characterised in that the Group II or Group III salt(s) of a C8 to C24 aliphatic monocarboxylic acid employed in step (a) are implemented in the form of a dry powder, and preferably features a d98 of 20 microns according to screen residue measurement performed with 20 microns DIN screens. 
Postupak prema bilo kojem od zahtjeva 1 do 10, naznačen time da sol odnosno soli Skupine II ili Skupine II C8 do C24 alifatske monokarboksilne kiseline koja se koristi u koraku (a) se primjenjuju u obliku suhog praha, te poželjno imaju dog od 20 mikrona prema mjerenju ostatka prosijavanja provedenog sa DIN sitima od 20 mikrona.
Step of Mechanical-Chemical Treatment of the Aqueous Phase 
Broj objave europskog patenta:
Another object of the invention is a use for the preparation of a pharmaceutical composition of a mixture containing a zinc-hyaluronan complex active agent in admixture with a carrier and/or additive conveniently used in medicine to obtain the composition. 
Još jedan predmet izuma je upotreba za pripravu farmaceutskog sastava smjese koja sadrži cink-hijaluronan kompleks kao aktivnu tvar u smjesi sa nosačem i/ili aditivom uobičajeno korištenim u medicini, kako bi se dobio sastav.
A method according to any of the previous claims, wherein the industrial by-products containing Fe(II) are waste materials or currents in liquid, solid or semi-solid form containing ferrous sulphates or other salts of mainly Fe(II). 
Metoda u skladu sa bilo kojim od prethodnih patentnih zahtjeva, pri čemu industrijski sporedni proizvodi koji sadrže Fe(Il) su otpadni materijali ili struje u tekućem, čvrstom ili polučvrstom obliku koji sadrže ferosulfate ili druge soli uglavnom Fe(1]).
the coding unit determiner (120) generates the information about a partition type of the coding unit of the coded depth and the information about a prediction mode of the coding unit of the coded depth, wherein the partition type is determined to indicate at least one prediction unit obtained from the coding unit of the current depth, and prediction is performed in the prediction mode on the coding unit of the current depth based on the at least one prediction unit, and 
kada informacija o podijeli označava da se kodirajuća jedinica trenutne dubine ne može više dijeliti, dekoder (230) je podešen da određuje veći broj jedinica predviđanja u kodirajućoj jedinici trenutne dubine, provodi među predviđanje na mnoštvu jedinica predviđanja, određuje jednu ili više jedinica transformacije u kodirajućoj jedinici trenutne dubine i provodi inverznu transformaciju na jedinicama transformacije.
The process according to claim 12, wherein part of the excipients, such as part of a disintegrant or a diluent, are added extragranular prior to the final blending of step g. 
Postupak u skladu sa zahtjevom 8, naznačen time, da je dio pomoćnih sredstava dodan ekstragranularno prije završnog miješanja u koraku g.
1(c) SEQ ID NO:1 for CDR-H1, a CDR having the sequence given in FIG. 
Protutijelo prema zahtjevu 1, naznačeno time što teški lanac sadrži sekvencu navedenu u SEQ ID NO:15.
The composition of Claim 39,wherein said AChE inhibitor is tacrine, donepezil, rivastigmine, or galantamine. 
Pripravak iz Zahtjeva 17, naznačen time da navedeni inhibitor AChE pripada skupini takrina, donepezila, rivastigmina ili galantamina.
a heater assembly, fluidly coupleable between said working medium reservoir and said reactor chamber, and adapted to transfer energy to said working medium, so as to provide the energized fluid substance at a predetermined temperature and pressure into said reactor chamber of said fuel activation and energy release apparatus. 
sklop (400) grijača koji se može fluidno spregnuti između navedenog rezervoara (402) za radni medij i navedene komore (103) reaktora, i koji je prilagođen da prenosi energiju na navedeni radni medij tako da osigura isporučivanje pobuđene supstance u obliku fluida na unaprijed određenoj temperaturi i tlaku u navedenu komoru (103) reaktora navedenog uređaja za aktivaciju goriva i otpuštanje energije.
The polypeptide of claim 1, which additionally comprises a further domain and a third peptide linker at the C-terminal end. An isolated nucleic acid molecule encoding the fusion polypeptide of claim 6 . 
Molekula nukleinske kiseline koja kodira fuzijski polipeptid bilo kojeg zahtjeva 1-8, poželjno u operativnom spoju sa slijedom za kontrolu ekspresije.
A compound of formula wherein W2 represents a suitable leaving group and wherein the variables are defined as in claim 1. 
Spoj s formulom naznačen time da W2 predstavlja prikladnu odlazeću skupinu i pri čemu su varijable definirane kao u zahtjevu 1.
The compound of any of claims 1-12, or a pharmaceutically acceptable salt thereof, wherein B3 is H or C1-C6 alkyl. 
Tvar iz bilo kojeg od patentnih zahtjeva 1-12, ili njena farmaceutski prihvatljiva sol, pri čemu je B3s H ili C;-Cg alkil.
An antibody of any one of items 1 to 14, a conjugate of item 16 or a pharmaceutical composition of item 17 for use in a method of treating or preventing a disease or disorder involving cells expressing CLD18. 
Protutijelo sukladno patentnom zahtjevu 1, konjugat sukladno patentnom zahtjevu 3 ili farmaceutski pripravak sukladno patentnom zahtjevu 4 za uporabu u postupku liječenja ili prevenciju bolesti ili poremećaja koji uključuje stanice koje eksprimiraju CLD18A2.
Without addressing these problems, real progress in the pharmacotherapy of depression and anxiety disorders is not likely to happen. 
Bez nastojanja rješavanja tih problema neće doći do stvarnog napretka u farmakoterapiji poremećaja depresije i tjeskobe.
Another aspect of the invention is concerned with a beverage or foodstuff that is resistant to light induced flavour changes, wherein the beverage or foodstuff is obtained or obtainable by a method of manufacture that comprises introducing the present light stabilising composition into said beverage or foodstuff. 
Još jedan aspekt izuma se odnosi na piće ili prehrambeni proizvod koji je otporan na promjene arome inducirane svjetlom, pritom piće ili prehrambeni proizvod se dobiva ili se može dobiti postupkom proizvodnje koji sadržava uvođenje sadašnjeg pripravka za stabiliziranje na svjetlo u spomenuto piće ili prehrambeni proizvod.
The TNF family ligand trimer-containing antigen binding molecule of claim 1, comprising at least one moiety capable of specific binding to a target cell antigen and 
Molekula koja veže antigen i sadrži trimer TNF ligand obitelji prema patentnom zahtjevu 1, naznačena time, da član TNF ligand obitelji kostimulira aktivaciju ljudske T-stanice.
A pharmaceutical composition comprising a compound according to any one of claims 1-13 or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier, adjuvant or vehicle. 
Kompozicija koja sadrži spoj koji ima strukturu i farmaceutski prihvatljiv nosač, prijenosnik ili adjuvans za upotrebu kao lijek za liječenje infekcije virusa gripe.
The monolithic radiant panel as claimed in claim 1, wherein the monolithic radiant panel is coated with a material such that the monolithic radiant panel has an emissivity of about 0.90 to about 0.99. 
Sustav s monolitnim radijativnim panelom u skladu s patentnim zahtjevom 1, naznačen time što je monolitni radijativni panel (100) obložen takvim materijal da monolitni radijativni panel (100) ima emitivnost od otprilike 0,90 do otprilike 0,99.
In Vitro Biological Activity 
In vitro biološko djelovanje
The rotation speed was set at 50±2 revolutions per minute, the dissolution medium being 0.1 N HCl maintained at a fixed temperature of 37° C. (pH 1.2 simulated gastric fluid). 
Rotacijska brzina bila je postavljena na 50 + 2 okretaja po minuti, medij za otapanje je bio 0,1 N HCI održavana na fiksnoj temperaturi od 37 *C (pH 1,2 simulirao je želučani sok).
A composition comprising a combination of at least two compounds chosen from the group consisting of irbesartan, idraparinux, otamixaban, SR48692, mecamylamine, clopidogrel, or salts or prodrugs or derivatives or sustained release formulations thereof, for simultaneous, separate or sequential administration. 
Sastav sadrži (i) najmanje jednu tvar odabranu između klopidogrela, cilostazola, tikolopidina, ili tirofibana, u kombinaciji s (ii) jednom tvari odabranom između mekamilamina, irbesartana, idraparinuksa ili otamiksabana, ili njihovih soli ili formulacija za postepeno oslobađanje za uporabu u liječenju neuroinflamacije.
preparing a leavened puff pastry dough or puff pastry dough comprising flour and water, 
(i) - priprema dizanog lisnatog tijesta ili lisnatog tijesta koja sadržavaju brašno i vodu,
Number of arms: 
Broj međunarodne objave:
In another embodiment, the tapping density was controllable in the range of 0.8-2.8 g/cm3. 
Prekursor materijal prema zahtjevu 1, u kome prekursor materijal ima nasipnu gustoću u rasponu od 0,8 do 2,8 g/cm3.
Bladder cancer. 
Rak mokraćnog mjehura.
Probes can be labeled with a detectable marker, such as, for example, a radioisotope, fluorescent compound, bioluminescent compound, a chemiluminescent compound, metal chelator or enzyme. 
Protutijelo ili fragment prema zahtjevu 6, naznačen(0) time, da je protutijelo ili fragment spojen/o na marker koji se može otkriti, pri čemu je taj marker radioizotop, metalni kelator, enzim, fluorescentni spoj, bio-iluminacijski spoj ili kemijsko-iluminacijski spoj.
A compound of formula (XII): 
Spoj formule (XII)
Data stream according to claim 7, wherein the transform coefficient block relates to a depth map content. Computer readable digital storage medium having stored thereon a computer program having a program code for performing, when running on a computer, a method according to claims 5 or 6. 
Digitalni medij za pohranu podataka, koji se može čitati preko računala, naznačen time, da obuhvaća pohranjen računalni program koji, dok je programski uključen na računalo, sadrži programski kod za izvršavanje postupka prema zahtjevima 14 ili 15.
The composition of claim 2, wherein the composition includes 22 mg/mL levamisole phosphate. 
Pripravak prema zahtjevu 2, naznačen time da pripravak sadrži količinu reda veličine 22 mg/mL levamizol fosfata.
p is independently 1 or 2; and y is 1 or 2. 
p je neovisno 1 ili 2; i y je 1 ili 2;
Analytical HPLC/MS was performed on Shimadzu LC10AS liquid chromatographs and Waters ZMD Mass Spectrometers using the following methods: 
Analitička HPLC/MS bila je izvedena na Shimadzu LC10AS tekućim kromatografima i Waters ZMD masenim spektrometrima primjenom slijedećih postupaka:
The pregnenolone derivative compound according to claims 1 or 2, wherein said compound is of formula (D): or a pharmaceutically acceptable salt thereof, wherein 
Tvar derivat pregnenolona u skladu s patentnim zahtjevom 1 ili 2, pri čemu je navedena tvar formule (D): [image] ili njena farmaceutski prihvatljiva sol, pri čemu:
The apparatus of claim 1, wherein a scan pattern for scanning the non-zero coefficients of each subset is same with the scan pattern for scanning the plurality of subsets. 
Uređaj prema zahtjevu 1, naznačen time da obrazac skeniranja za skeniranje zastavica označava je li odgovarajući koeficijent transformacije 0 ili ne isti kao obrazac skeniranja za skeniranje ne-nultih koeficijenata svakog podbloka.
is selected from pyrrolyl, triazolyl, thienyl or thiazolyl, which is optionally substituted one or more times with methyl, phenyl, benzoyl or pyridinyl; or 
se bira između pirolila, triazolila, tienila ili tiazolila, izborno jednom ili više puta supstituiranog s metilom, fenilom, benzoilom ili piridinilom; ili
For example the colourant mixture may comprise 10-50, typically 40+/−5, wt. % pigment, the balance up to 100% comprising the carrier material. 
Na primjer, mješavina sredstva za bojenje može sadržavati 10 - 50, tipično 40+/-5 masenih % pigmenta, pri čemu se kao balans do 100% nalazi materijal nosilac.
Compounds of the present invention may exist in various tautomeric forms. 
Spojevi prikazanog izuma mogu postojati u različitim tautomernim oblicima.
The single-layer printing method according to claim 2, characterized in that the combustion agent is a salt of an organic acids. 
Postupak jednoslojnog tiska prema Zahtjevu 7, naznačen time, što je agens za sagorijevanje sol organske kiseline.
The container according to any one of the previous claims, wherein the fluid guide element (36, 37, 38, 39, 40, 41) is in the form of a line or of several parallel lines (16, 17, 18). 
Spremnik u skladu s bilo kojim od prethodnih patentnih zahtjeva, naznačen time što je navodeći element za fluid (16, 17, 18) postavljen u obliku više paralelnih linija.
Wind system (1) according to claim 4, characterised in that said systems that actuate said spoiler contain fibres made of metallic shape-memory alloys. 
Vjetreni sustav (1) prema zahtjevu 7, naznačen time da su spomenuti permanentni magneti magneti od spoja neodimijuma, željeza i borona.
The term “hydroxyhydrocarbyl” as used herein refers to hydroxyl substituted hydrocarbyls. 
Termin "hidroksihidrokarbil", kako je ovdje upotrijebljen, se odnosi na hidroksil supstituirane hidrokarbile.
A composition according to claim 27 or a compound according to claim 1 or claim 14 for treating or alleviating a disease or disorder selected from immune responses such as allergic or type I hypersensitivity reactions or asthma; autoimmune diseases such as transplant rejection, graft versus host disease, rheumatoid arthritis, amyotrophic lateral sclerosis, or multiple sclerosis; neurodegenerative disorders; or solid and hematologic malignancies,;or hypertension, angina pectoris, cerebrovascular contraction, asthma, peripheral circulation disorder, premature birth, cancer, erectile dysfunction, arteriosclerosis, spasm (cerebral vasospasm and coronary vasospasm), retinopathy (e.g., glaucoma), inflammatory disorders, autoimmune disorders, AIDS, osteoporosis, myocardial hypertrophy, ischemia/reperfusion-induced injury, or endothelial dysfunction. 
Upotreba u skladu s patentnim zahtjevom 56, naznačena time što navedena bolest je hipertenzija, angina pektoris, cerebrovaskularna kontrakcija, astma, poremećaj perifernog krvotoka, prijevremeni porod, rak, erektilna disfunkcija, arterioskleroza, spazam (cerebralni vazospazam i koronarni vazospazam), retinopatija (primjerice glaukom), upalni poremećaji, autoimuni poremećaji, AIDS, osteoporoza, hipertrofija miokarda, ishemijsko-reperfuzijska ozljeda ili disfunkcija endotela.
A computer-readable medium having computer-executable instructions adapted to cause a 3D printer to print an anchor according to claim 1 . 
Računalo čitljiv medij s uputama koje se mogu izvršiti na računalu prilagođenima da se na 3D printeru ispisuje sidro (1) prema bilo kojem od prethodnih zahtjeva.
a sarcoma, lung cancer, gastrointestinal cancer, genitourinary tract cancer, liver cancer, bone cancer, nervous system cancer, gynecological cancer, or skin cancer; or 
sarkom, karcinom pluća, gastrointestinalni karcinom, karcinomgenitourinarnog trakta, karcinom jetre, karcinom kosti, karcinom živčanog sustava, ginekološki karcinom, ili karcinom kože; ili
The composition according to claim 1, wherein component (A) is 3-difluoromethyl-1-methyl-1H-pyrazole-4-carboxylic acid (9-dichloromethylidene-benzonorbornene-5-yl)amide. 
Spoj prema zahtjevu 1, naznačen time, da sadrži kao komponentu (A) spoj (9-diklorometiliden-benzonorbornen-5- iDamid 3-difluorometil-1-metil-1H-pirazol-4-karboksilne kiseline, te kao komponentu (B) mandipropamid.
where RD is independently selected from R, CO2R, COR, CHO, CO2H, and halo; R6 and R9 are independently selected from H, R, OH, OR, SH, SR, NH2, NHR, NRR', NO2, Me3Sn and halo; is independently selected from H, R, OH, OR, SH, SR, NH2, NHR, NRR', NO2, Me3Sn and halo; RL is a linker for connection to a cell binding agent selected from an antibody, a fragment of an antibody that contains at least one binding site and a cyclic polypeptide; 
i R9su neovisno odabrani od sljedećih: H, R, OH, OR, SH, SR, NH2, NHR, NRR’, NO2, Me3Sn i halogen;R7je neovisno odabran od sljedećih: H, R, OH, OR, SH, SR, NH2, NHR, NRR’, NO2, Me3Sn i halogen;RLje poveznica za spajanje na sredstvo za vezanje stanice odabrano od protutijela, fragmenta protutijela koji sadrži barem jedno vezno mjesto, te cikličkog polipeptida;
Method of recycling by treatment of ceramic parts in a device for treatment, the parts being provided for use in the industry of artificial synthetic fibers, characterized in that, it takes place in three stages, namely: ceramic part (A) preparation, treatment of the surface of the ceramic part (A) with abrasive material (B) and final treatment with optical control. 
HR P20151142 T1 PATENTNI ZAHTJEVI Postupak recikliranja obradom keramičkih dijelova u uređaju za obradu, keramički dijelovi se koriste u proizvodnji umjetnih sintetičkih vlakana, naznačen time da se odvija u tri faze, i to: priprema keramičkog dijela (A), obrada površine keramičkog dijela (A) s abrazivnim materijalom (B) i završna obrada s optičkom kontrolom.
RA and RB are independently selected from the group consisting of hydrogen, alkyl, and alkylcarbonyl; and RC and RD are independently selected from the group consisting of hydrogen and alkyl. for use in a method of treating cancer 
RA i Rs su neovisno odabrani iz skupine koja se sastoji od vodika, alkila i alkikarbonila; 1 Rc i Rp su neovisno odabrani iz skupine koja se sastoji od vodika 1 alkila, Spoj u skladu s patentnim zahtjevom 2, naznačen time, da je A odabran od skupine koja se sastoji od ara),
In one embodiment of the methods provided above, the hydrolysate is a plant hydrolysate. 
Postupak u skladu s patentnim zahtjevom 2, naznačen time što je hidrolizat biljni hidrolizat ili hidrolizat soje.
wherein R1, R2 and B1 have the meanings indicated in claim 1 and X is Cl, Br or I, in a Suzuki reaction with a boronic acid derivative B2—B(OH)2, in which B2 has the meaning indicated in claim 1, and/or a base or acid of the formula I is converted into one of its salts. 
HR P20120549 T1 formula (Il) pri čemu R', R* i B' imaju značenja navedena u zahtjevu 1 i X is Cl, Brili I, reagira u Suzukijevoj reakciji sa derivatom boronske kiseline B'-B(OH),, gdje B* ima značenje navedeno u zahtjevu 1, ifili baza ili kiselina formule I je pretvorena u jednu od njegovih soli.
A support member assembly according to claim 3 or 4, wherein the slots (120,120',120") are provided on all four sides (1 02a, 1 02b, 1 03a, 1 03b) of the elongate support member (102,103). 
Konstrukcija nosećeg elementa prema jednom od patentnih zahtjeva 3 ili 4, gdje su prorezi (120, 120', 120") napravljeni za sve četiri strane (102a, 102b, 103a, 103b) produžnog nosećeg elementa (102, 103).
Integrated in the central layer 33 are in this case two horizontal beams 35, 36 made from wood or another suitable material such as plastic or the like. 
U ovom slučaju u središnjem sloju 33 integrirane su dvije vodoravne grede 35, 36 izrađene od drva ili drugog prikladnog materijala kao što je plastika ili slično.
placing a reinforcement package (2) against the molding wall; 
- < stavljanje tijela za ojačanje (2) na stijenku kalupa;
A clip (7, 7') as claimed in claim 25, wherein the intermediate portion (73,73') comprises three angled sections (73a, 73b, 73c). 
Držač (7, 7') u skladu s patentnim zahtjevom 25, kod kojega srednji dio (73, 73') ima tri sekcije koje su pod kutom (73a, 73b, 73c).
The process according to any one of claims 1 or 2, characterized in that from 40 to 85 wt%, preferably from 45 to 80 wt%, more preferably from 50 to 75 wt%, most preferably from 60 to 70 wt%, e.g. 65 wt% of the at least one mineral material particles in step a) have an equivalent spherical diameter of < 10 µm. 
Postupak prema bilo kojem od zahtjeva 1 ili 2, naznačen time da od 40 do 85 % tež., poželjno od 45 do 80 % tež., poželjnije od 50 do 75 % tež., najpoželjnije od 60 do 70 % tež., npr. 65 % tež. čestica najmanje jednog mineralnog materijala u koraku a) imaju ekvivalentni sferični promjer od < 10 um.
Photovoltaic plant as in any claim hereinbefore, characterized in that said heat conductor material is charged with TiO2, graphite, SiC and Al2O3 in order to have good heat conductor characteristics. 
Fotonaponski uređaj prema bilo kojem prethodnom zahtjevu, naznačen time da se navedeni materijal koji provodi toplinu puni sa TiO», grafitom, SiC i Al)0, kako bi imao dobre karakteristike toplinske vodljivosti.
Preferably a mixture of methanol and water is used as the solvent. 
Kao otapalo poželjno se koristi smjesa metanola i vode.
This assay determines the ability of a test compound to inhibit the tail current flowing through the human ether-a-go-go-related-gene (hERG)-encoded potassium channel. 
Ovim testom mjeri se sposobnost ispitivanog spoja da inhibira tok struje kroz humani, (NERG)-om kodirani, kalijev kanal srodan genu ether-a-go-go.